Immuno-Oncology | Specialty

Long-Term Follow-up Sustains Frontline Nivolumab/Ipilimumab Benefit in Melanoma

June 7th 2016

At a minimum follow-up of 18 months, the combination of nivolumab and ipilimumab reduced the risk of disease progression by 58% compared with ipilimumab alone, and single-agent nivolumab lowered the risk of progression by 45% versus ipilimumab monotherapy in patients with advanced melanoma.

Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma

June 7th 2016

David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).

PD-L1 Inhibitor Avelumab Active in Advanced Mesothelioma

June 7th 2016

Avelumab demonstrated clinical activity in patients with advanced or unresectable mesothelioma, with an overall response rate of 14.3%.

Nivolumab Improves OS, ORR in Phase III Head and Neck Cancer Study

June 7th 2016

Treatment with single-agent nivolumab improved overall survival and objective response rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Nivolumab Delivers Durable Responses in Hodgkin Lymphoma

June 6th 2016

Single-agent nivolumab induced responses in 66% of patients with classical Hodgkin lymphoma who had progressed following autologous stem cell transplant and brentuximab vedotin.

Nivolumab 5-Year OS Rate Passes 30% in Advanced RCC

June 6th 2016

About one third of patients with advanced renal cell carcinoma who were treated with single-agent nivolumab in the second-line setting or later were still alive at 4 and 5 years in long-term follow-up data from phase I and phase II clinical trials.

Atezolizumab Effective in First-Line Setting in Bladder Cancer

June 6th 2016

Patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months after taking the immunotherapy agent atezolizumab (Tecentriq).

Bernard Fox on Significance of Immunoscore Validation Project

June 6th 2016

Bernard A. Fox, PhD, chief, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute at Providence Portland Medical Center, discusses the significance of the Immunoscore Validation Project.

Dr. Balar on IMvigor 210 Results for Metastatic Urothelial Carcinoma

June 6th 2016

Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.

Novel Gastric Cancer Immunotherapy Scores Robust Phase II Results

June 6th 2016

IMAB362 reduced the risk of death or progression by approximately 50% when added to standard chemotherapy for patients with CLDN18.2-positive advanced gastric cancers.

Nivolumab/Ipilimumab Combo Active in Microsatellite Instability-High mCRC

June 6th 2016

Nivolumab (Opdivo) as a monotherapy and in combination with ipilimumab (Yervoy) demonstrated promising antitumor activity in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.

Nivolumab/Ipilimumab Frontline Response Nears 60% in PD-L1+ NSCLC

June 5th 2016

Upfront treatment with the combination of nivolumab and ipilimumab demonstrated an objective response rate of 57% in patients with PD-L1-positive advanced non–small cell lung cancer.

Adding 4-1BB Agonist to Pembrolizumab Safe, Effective Across Solid Tumors

June 5th 2016

The combination of the 4-1BB agonist utomilumab and the PD-1 inhibitor pembrolizumab was safe and effective as a treatment for patients with advanced solid tumors.

Nivolumab Survival Benefit Sustained in Long-Term NSCLC Outcomes

June 5th 2016

Two-year follow-up data showed sustained improvements in overall survival with nivolumab in pretreated patients with either nonsquamous or squamous non–small cell lung cancer in updated findings from the phase III CheckMate-057 and -017 trials.

Nivolumab Safe, Effective in Early Stage Glioblastoma Study

June 5th 2016

Single-agent nivolumab demonstrated encouraging signs of activity with a mild adverse event profile for patients with recurrent glioblastoma multiforme.

Nivolumab/Ipilimumab Combination Active in Recurrent SCLC

June 4th 2016

Treatment with the combination of nivolumab and ipilimumab demonstrated a median overall survival of 7.7 months and a 1-year OS rate of 43% for patients with recurrent small cell lung cancer.

Dr. Borghaei on 2-Year Findings With Nivolumab Vs Docetaxel in NSCLC

June 4th 2016

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).

Dr. Madhav Dhodapkar on IMiD-based Combinations in Multiple Myeloma

June 2nd 2016

A Look Ahead in Genitourinary Cancers

June 1st 2016

The Role of Biomarkers in Bladder Cancer

June 1st 2016